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ABSTRACT: Melioidosis is an emerging infectious disease
caused by Burkholderia pseudomallei and is associated with high
morbidity and mortality rates in endemic areas. Antibiotic
treatment is protracted and not always successful; even with
appropriate therapy, up to 40% of individuals presenting with
melioidosis in Thailand succumb to infection. In these
circumstances, an eﬀective vaccine has the potential to have a
dramatic impact on both the scale and the severity of disease.
Currently, no vaccines are licensed for human use. A leading
vaccine candidate is the capsular polysaccharide consisting of a
homopolymer of unbranched 1→3 linked 2-O-acetyl-6-deoxy-β-
D-manno-heptopyranose. Here, we present the chemical syn-
thesis of this challenging antigen using a novel modular
disaccharide assembly approach. The resulting hexasaccharide was coupled to the nontoxic Hc domain of tetanus toxin as a
carrier protein to promote recruitment of T-cell help and provide a scaﬀold for antigen display. Mice immunized with the
glycoconjugate developed IgM and IgG responses capable of recognizing native capsule, and were protected against infection
with over 120 × LD50 of B. pseudomallei strain K96243. This is the ﬁrst report of the chemical synthesis of an immunologically
relevant and protective hexasaccharide fragment of the capsular polysaccharide of B. pseudomallei and serves as the rational
starting point for the development of an eﬀective licensed vaccine for this emerging infectious disease.
■ INTRODUCTION
Melioidosis is a serious and often fatal disease caused by the
Gram negative, facultative intracellular pathogen Burkholderia
pseudomallei.1 The disease is prevalent in South-East Asia and
Northern Australia, although the area of endemicity is
expanding rapidly as surveillance improves and cases are
described in other countries (ref 2; see www.melioidosis.info
for up-to-date global distribution). The clinical presentation of
melioidosis is varied, ranging from localized infections and
abscess formation through to acute pulmonary infections and
fulminating septicaemias.3,4 Antibiotic therapies are available for
melioidosis, typically requiring several weeks of intravenous
administration followed by orally delivered antibiotics which
may last several months.5 Overall mortality in individuals
presenting with melioidosis at medical facilities varies by
country (∼40% in Thailand, ∼15% in Australia), but mortality
can be up to 90% with septicaemic melioidosis, even with
appropriate antibiotic therapy.4,6,7 Due to the nonspeciﬁc
presentation, the rapid course of disease, the intrinsic resistance
of B. pseudomallei to commonly used antibiotics, and the risk
posed by aerosolized bacteria if deliberately released, B.
pseudomallei is currently classiﬁed as a CDC Tier 1 Select
Agent under 42 CFR Part 73 (see http://www.selectagents.
gov/).
At present there is no licensed vaccine to protect against
melioidosis. Considerable work has been undertaken to identify
and develop vaccine candidates which will protect humans
against melioidosis (for recent reviews, see refs 8−10). From
these studies, the manno-heptopyranose capsular polysacchar-
ide (CPS) has emerged as a leading candidate. This
polysaccharide is a homopolymer of unbranched 1→3 linked
2-O-acetyl-6-deoxy-β-D-manno-heptopyranose11,12 and is a
major virulence determinant in B. pseudomallei.13,14 Interest-
ingly, B. pseudomallei appears to express only this single
serotype of capsule and it is present in all reported isolates; the
same is true for all isolates of the related pathogen Burkholderia
mallei, the causative agent of glanders.15 A capsule-based
vaccine would therefore potentially oﬀer cross-species
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protection against both pathogens. Recent work has demon-
strated that CPS puriﬁed from B. pseudomallei induces
protective immunity against experimentally induced melioidosis
in mice16 and that immune responses and protection can be
signiﬁcantly improved through conjugation of the polysacchar-
ide to a carrier protein.17,18 However, current methodology
requires that CPS is puriﬁed from bacteria in containment (at
least BioSafety Level 2), a manufacturing process which is both
technically demanding and expensive, and may not readily
translate to commercial scale manufacturing. Moreover, the
puriﬁed native CPS also displays heterogeneity of chain length
and may contain copuriﬁed endotoxin or other polysacchar-
ides,19 introducing complications to analysis, handling, and
quality control. A synthetic source of CPS wherein all structural
features of the antigen are unequivocally deﬁned and
established chemical manufacturing infrastructure could be
utilized would be more appropriate as a choice for the antigen
in a CPS-based vaccine.
The B. pseudomallei/mallei CPS presents a variety of
structural aspects that render it a challenging target for
chemical synthesis. Speciﬁcally, β-mannoside linkages are
traditionally problematical20 and the presence of the one-
carbon chain-extension at the pyranose C-6 precludes standard
implementation of approaches to β-mannosides using 4,6-
benzylidene protected donors developed by the Crich group20
and adapted by others.21,22 Furthermore, the presence of the
potentially labile and migration prone 2-O-acetyl group on each
residue necessitates a highly engineered protecting group
strategy; this group has been shown to be necessary for antigen
recognition by monoclonal antibodies,23 although whether this
is relevant to protective immunity has not been examined. A
recent study has detailed an elegant approach to the synthesis
of a protected β-(1,3)-linked manno-heptopyranose disacchar-
ide24 utilizing installation of the C-6 one-carbon chain
extension at the monosaccharide stage and chain extension
via intramolecular aglycon delivery. However, this work did not
extend the glycan chain past the disaccharide stage or
investigate whether this disaccharide could induce protective
immune responses.
This work describes a novel approach to the chemical
synthesis of a 1→3 linked 2-O-acetyl-6-deoxy-β-D-manno-
heptopyranose hexasaccharide using a modular disaccharide
assembly approach. This hexasaccharide was covalently linked
to a recombinant carrier protein to improve immunogenicity
and the resulting glycoconjugate shown to stimulate production
of antibodies speciﬁc for native CPS and to confer signiﬁcant
protection in mice following a challenge with a lethal dose of B.
pseudomallei.
■ RESULTS AND DISCUSSION
Retrosynthetic Analysis of Capsular Antigen Target 1.
Synthetic hexameric capsular polysaccharide antigen 1 (SHCPS)
was designed to incorporate all of the distinguishing structural
features of the natural polysaccharide in addition to a reducing
end linker moiety that would allow for directed conjugation to
a carrier protein (Figure 1). The choice of a hexasaccharide
versus a target of diﬀerent length would simultaneously provide
a size likely to be immunologically relevant,25,26 although the
minimum protective epitope for this antigen is not currently
known, and would provide a vehicle for development of an
eﬃcient modular assembly approach for the synthesis of
antigens and fragments featuring an even number of repeating
heptosides. In designing the synthesis there was a need to
identify assembly and ﬁnal deblock sequences that minimized
manipulation and complex chemical operations on large,
potentially sensitive synthetic intermediates. In an eﬀort to
identify an eﬃcient route with a high probability of success,
many strategies were considered, including: (i) assembly of a β-
mannopyranose oligosaccharide framework followed by in-
stallation of the C-6 one-carbon chain extension on each
monosaccharide residue either sequentially or en masse. While
this approach would allow implementation of the proven β-
mannoside synthesis methodology,20 it would require six
multistep C-6 homologations during assembly; (ii) installation
of the C-6 one-carbon chain extension at the monosaccharide
building block stage, followed by assembly of a poly-β-D-gluco-
heptopyranose hexasaccharide and performing six inversions at
the C-2 position of each residue to establish the desired β-D-
manno-heptose stereochemistry. This option would require
signiﬁcant late stage manipulation of a fully assembled
hexasaccharide and would rely on the C-2 position in every
monosaccharide residue being sterically accessible for inversion;
(iii) installation of the C-6 one-carbon chain extension at the
monosaccharide stage but assemble the hexasaccharide back-
bone via intramolecular aglycon delivery.27 Indeed, this
approach has recently been described for the synthesis of a
protected β-(1,3)-linked manno-heptopyranose disaccharide.24
The reservations with this strategy, however, were the
uncertainty of the eﬃciency of this methodology for assembling
larger oligosaccharides and the considerable manipulation that
would be required on valuable advanced synthetic intermedi-
ates. Recent publications during the completion of this work
have indeed demonstrated the successful implementation of
intramolecular aglycon delivery for assembly of large
oligosaccharides;28,29 therefore, intramolecular aglycon delivery
represents a potential alternative approach to oligosaccharides
such as (1).
Thus, the initial strategy was centered on option (ii) using a
C-6 homologated gluco-conﬁgured monosaccharide building
block, which was to be used for iterative coupling to form β-
gluco-heptopyranose linkages during assembly. In this case,
inversion at C-2 of the nonreducing end residue would be
performed at each assembly iteration to yield the desired β-
manno conﬁguration. Such a strategy, based on a C-2 keto-
donor followed by postcoupling reduction, was implemented
successfully for the construction of a C. albicans derived poly-β-
Figure 1. Manno-heptopyranose antigens in this study. (A) Structure
of natural capsular polysaccharide from B. pseudomallei. In this
rendering the polysaccharide is anchored to a lipooligosaccharide
(LOS) at the reducing end, although it should be noted that the
molecule to which the capsule is anchored is not currently known. (B)
Structure of synthetic hexameric capsular polysaccharide target antigen
1.
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mannoside30 based on the pioneering work by Lichtenthaler.31
More recently, a postcoupling C-2 inversion approach via C-2
triﬂate ester displacement by azide was utlilized to achieve the
β-D-ManNAcA conﬁguration en route to the synthesis of the
repeating unit of the S. aureus type 5 capsular polysaccharide.32
While this approach circumvents the challenges associated with
multiple late-stage inversion transformations, and indeed was
successful for smaller oligosaccharides, the signiﬁcant amount
of manipulation required on larger structures was a major
concern. As a result, modest re-engineering of the strategy
allowed implementation of a modular disaccharide assembly
approach using key disaccharide building block 2 (Figure 2),
which was amenable to large-scale preparation from a single
monosaccharide building block 5 and had the majority of the
required stereochemistry and functionality already built in.
Speciﬁcally, building block 2 incorporated the requisite C-6
chain extensions and a β-manno-heptose linkage between the
two monosaccharide residues. The reducing end gluco-heptose
residue, which served as the donor group during assembly, was
ﬁtted at C-2 with the 4-acetoxy-2,2-dimethyl butanoyl (ADMB)
ester,33 a participating ester group to control the glycosylation
stereochemistry, minimize the potential for orthoester for-
mation during assembly, and enable regioselective liberation of
the C-2 hydroxyl for subsequent inversion to the β-manno
conﬁguration. Benzoyl esters were also considered, but
benzoates were envisaged as protecting groups for the
manno-C-2 positions in the growing chain to allow late-stage
installation of the critical 2-O-acetates in the ﬁnal structure. The
protecting group for the manno-C-3 position required facile and
selective removal to liberate the 3-hydroxyl as the acceptor for
the next assembly cycle. Many protecting groups with reactivity
orthogonal to that of the benzoyl and ADMB esters were
evaluated in scouting studies, but it was concluded that the use
of O-acetates for both manno-C-3 and manno-C-2 would be the
most reliable and, if necessary, would accommodate multiple
approaches throughout assembly. Speciﬁcally, exploiting well-
established regioselective coupling to the 3-position of a 2,3-
diol mannose acceptor34 would streamline assembly; however,
if the selectivity proved unacceptable or made subsequent
analysis too diﬃcult, the option remained to use 2,3-
orthobenzoate formation followed by regioselective opening
to the 2-O-benzoyl leaving the 3-hydroxyl open as the only
possible acceptor. This strategy ultimately proved successful as
it minimized the amount of manipulation of larger intermediate
structures and enabled the development of a standard protocol
for each iterative cycle during assembly. Use of benzyl ethers as
stable protecting groups for the C-4 and C-7 hydroxyls and
benzyl protecting groups for the linker nitrogen would set the
stage for a ﬁnal global deprotection step.
Building Block Synthesis. The monosaccharide building
blocks 3 and 4 en route to key disaccharide 2 were prepared
from a common glycal intermediate 7 (Figure 3), which is
available in seven steps from the known mannose derivative
5.35,36 Elaboration of 7 to the common advanced intermediate
8 was achieved in seven steps with 65% overall yield by ﬁrst
installing the p-methoxybenzyl (PMB) ether at C-3 followed by
osmium-catalyzed dihydroxylation of the β-face of the glycal.
Subsequent acetylation, selective removal of the anomeric
acetate using benzylamine, trichloroacetimidate formation,
installation of the allyl glycoside, and ﬁnal removal of the 2-
O-acetyl group completed the formation of 8. The stereo-
chemistry of intermediate 8 was veriﬁed using a combination of
1-D and 2-D nuclear magnetic resonance (NMR) spectroscopy.
From 2-D 1H−13C correlation (HSQC) experiments the H-1
signal was identiﬁed as a doublet (3JH1H2 = 7.3 Hz) at 4.31 ppm
due to its correlation to the anomeric 13C signal at 101.73 ppm.
From this assignment the ring H-2 H-3 and H-4 ring protons
were easily identiﬁed from the COSY spectrum (H-2:3.63 ppm,
dd, 3J = 9.1, 7.3 Hz; H-3:3.33 ppm, t, 3J = 9.1 Hz; H-4, 3.53
ppm, t, 3J = 9.1 Hz). Taken together, these coupling constants
are consistent with an all-trans-equatorial pyranose ring, i.e., β-
gluco conﬁgured. With the structure of 8 ﬁrmly established and
material available in signiﬁcant quantity, it was split and
transformed in parallel to monosaccharides 3 and 4 as follows.
Benzoylation at C-2 of intermediate 8 using benzoyl chloride in
pyridine in the presence of DMAP followed by cerium(IV)
ammonium nitrate-mediated cleavage of the 3-O-PMB ether
gave 3 in 96% overall yield. In parallel, donor 4 was produced
by installing an ADMB ester at C-2 of 8 using ADMB chloride,
pyridine, and DMAP followed by removing the 3-O-PMB ether
via cerium(IV) ammonium nitrate, benzoylation at C-3, and
two-step removal of the anomeric allyl group using Felkin’s
catalyst and OsO4 to give the lactol. The lactol was ﬁnally
transformed into the trichloroacetimidate donor 4 by reaction
with 2,2,2-trichloroacetonitrile under catalysis by K2CO3.
Coupling of 3 with the donor 4 gave exclusively the β-linked
disaccharide 9 due to the presence of the 2-O-ADMB group,
which subsequently was removed in high yield using acetyl
chloride in methanol to give 10. The protecting group
arrangement in 10 was conducive to facile inversion at C-2 of
the nonreducing residue via triﬂate ester formation followed by
sonication-induced displacement with tetra-n-butylammonium
acetate37 to give the manno-gluco disaccharide intermediate 11
in 77% yield with no detectable gluco-gluco isomer. Pan removal
of the ester protecting groups in 11 gave triol 12, which after
2,3-acetonide and ADMB ester installation gave 14. Replace-
ment of the 2,3-acetonide with acetate esters gave the key
Figure 2. Retrosynthetic analysis of manno-heptopyranose capsular
antigen target 1. Synthetic strategy to allow modular assembly of the
1→3 linked 2-O-acetyl-6-deoxy-β-D-manno-heptopyranose hexasac-
charide target antigen 1.
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disaccharide 2, which provided a convenient point for storing
material for future assembly operations, and may be elaborated
conveniently to either a modular donor or acceptor. In
preparation for iterative assembly, two-step cleavage of the
allyl glycoside and reaction of the resulting hemiacetal with
trichloroacetonitrile gave the key disaccharide donor 17, also a
stable intermediate that could be stored in the freezer for
months.
Assembly to Protected Hexasaccharide. Assembly of
the hexasaccharide backbone was achieved via three iterative
multistep coupling cycles starting with installation of a masked
amine linker synthon at the reducing end of the saccharide
backbone (Figure 4). Trimethylsilyl triﬂuoromethanesulfonate
(TMSOTf)-mediated coupling of 17 with the protected linker
acceptor 1838 gave the desired β-anomer 19 in 87% yield.
Sodium methoxide catalyzed removal of the three ester groups
in 19 gave triol 20, the 2,3-cis-diol of which was protected by an
acetonide ketal to give alcohol 21. With the C-2 alcohol group
of the gluco-residue now isolated, inversion to the manno-
conﬁguration was achieved through a two-step process
involving oxidation to the ketone using Dess-Martin period-
inane39 followed by reduction of the crude ketone using
NaBH4. The reduction proceeded cleanly in less than 5 min
with 9:1 stereoselectivity in favor of the desired manno-manno
conﬁgured disaccharide 22. While 22 was separable from the
manno-gluco disaccharide 21 at this stage, which presented an
opportunity to recycle recovered 21, it was found that for
subsequent larger runs the mixture could be carried through the
next two steps without impact on yield or quality of the
product. Thus, the 1:9 mixture of 21:22 was benzoylated at the
C-2 and after removal of the acetonide gave diol 23 in 55%
overall ﬁve-step yield from 20. The structure of 23 was
established by a combination of 1-D and 2-D NMR
spectroscopy with a particular focus on on two properties: (i)
the 1JC1,H1 coupling constant, and (ii) the downﬁeld broad
singlet signals corresponding to the C-2 ring protons of β-
manno anomeric linkages. These signals would prove diagnostic
for determining the stereochemistry of the anomeric linkages
during assembly of larger oligosaccharides. In the case of 23 the
1JC1,H1 for the two anomeric carbons were 155.2 and 157.8 Hz,
indicative of β-linked D-pyranoses.40 To provide further support
of the structural assignment of 23, a sample of the manno-gluco
isomer 21 was treated with benzoyl chloride then acetic acid to
give an authentic sample of diol 24, NMR analysis of which
showed the expected downﬁeld triplet (ppm, 3J = Hz) for the
C-2 ring proton consistent with a β-gluco conﬁguration.
Coupling of disaccharide diol acceptor 23 with disaccharide
donor 17 at −20 °C resulted in tetrasaccharide alcohol 25 in
86% yield (Figure 5). After benzoylation of the remaining C-2
hydroxyl, the tetrasaccharide 26 was prepared for inversion of
Figure 3. Synthesis of disaccharide donor 17.Chemical manipulations involved in the preparation of the monosaccharide building blocks 3 and 4 and
their coupling to create precursor compound 9 ready for further elaboration to the disaccharide donor 17. Reagents and conditions: (a) 4-acetoxy-
2,2-dimethylbutanoyl chloride, pyridine, 4-(dimethylamino)pyridine, 80 °C, 12 h, 81%; (b) cerium(IV) ammonium nitrate, acetonitrile:H2O (9:1v/
v), 5 °C, 10 min; (c) benzoyl chloride, pyridine, 4-(dimethylamino)pyridine, rt, 12 h, 96%, steps p−q overall; (d) Felkin’s catalyst, tetrahydrofuran,
rt, 30 min; (e) OsO4, 4-methylmorpholine N-oxide, rt, 12 h, 91% steps r−s overall; (f) K2CO3 powder (−325 mesh), trichloroacetonitrile, rt, 12 h;
(g) trimethylsilyl triﬂuoromethanesulfonate 0.1 equiv, CH2Cl2, rt, 2 h, 95%; (h) acetyl chloride, methanol, CH2Cl2, 0 °C to rt, 12 h, 89%; (i)
pyridine, CH2Cl2, triﬂuoromethanesulfonic anhydride, 0 °C, 5 min; (j) tetrabutylammonium acetate, toluene, sonication, rt, 30 min, steps c−d 90%
overall; (k) sodium methoxide, methanol, tetrahydrofuran, rt, 12 h; (l) p-toluenesulfonic acid, acetone, 2,2-dimethoxypropane, rt, 30 min; (m) acetic
acid, H2O (4:1, v/v), 65 °C, 1 h; (n) acetic anhydride, pyridine, CH2Cl2, 4-(dimethylamino)pyridine, rt, 12 h, 65% steps e−i overall. For complete
reaction conditions, see Supporting Information. Bn = Benzyl; Bz = Benzoyl; All = Allyl; Ac = acetyl; TCA = trichloroacetimidate; ADMB = 4-
acetoxy-2,2-dimethyl butanoyl.
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the lone gluco-residue to the desired manno isomer. In contrast
to the disaccharide 19 which could accommodate removal of all
esters en route to isolating the gluco C-2 hydroxyl, the presence
of the benzoyl esters in 26 precluded the use of standard
sodium methoxide de-esteriﬁcation conditions. However,
others have demonstrated selective removal of acetyl esters in
the presence of benzoyl esters using magnesium methoxide.41,42
Indeed, treatment of 26 with magnesium methoxide smoothly
removed the acetyl esters including the acetyl ester of the
ADMB group, which spontaneously lactonized to give triol 27
in 75% yield. In analogy with triol 20, triol 27 was subjected to
the same process of acetonide installation, Dess-Martin
oxidation, sodium borohydride reduction, benzoylation, and
acetonide removal to give diol 30 in 43% overall ﬁve-step yield
from triol 27.
For the ﬁnal iteration, coupling of disaccharide donor 17
with diol acceptor 30 at −20 °C gave hexasaccharide 31 in 50%
direct yield along with recovery of 40% unreacted diol 30,
which was easily separated chromatographically and recycled
(Figure 5). Following the procedures used at the tetrasacchar-
ide level, hexasaccharide 31 was subjected to the same seven-
step sequence to achieve inversion at C-2 of the lone gluco-
isomer to aﬀord the hexasaccharide diol 32 in 31% overall yield
from 31. While hexasaccharide 32 could have been extended
further to the octasaccharide, and indeed a small amount of a
protected octasaccharide was produced, minor amounts of
partially debenzoylated byproducts were observed during the
sequence from 31 to 32, indicating the upper limit of the utility
of this modular approach was being approached. The last
hurdle prior to the deblock sequence was to diﬀerentiate the
nonreducing end 2,3-cis-diol to allow for future regioselective
incorporation of the 2-O-acetyl group. For this, the well-
established approach of 2,3-ortho-ester formation followed by
in situ dilute acid-catalyzed axial-selective ring opening to give
the C-2 ester was adapted.43,44 Thus, treatment of cis-diol 32
with trimethyl orthobenzoate gave the orthoester which was
rearranged selectively to the C-2 ester by addition of water to
the reaction mixture. Finally, the sole remaining hydroxyl group
at C-3 of the nonreducing end residue was benzylated under
acidic conditions using benzyl 2,2,2-trichloroacetimidate45 to
give hexasaccharide 33. With hexasaccharide 33 in hand, the
complete β-manno-heptose backbone was in place and all C-2
hydroxyl groups were diﬀerentiated and staged for future
incorporation of the 2-O-acetyl groups.
Final Elaboration and Deprotection. Final processing
and deprotection of 33 to synthetic antigen 1 was accomplished
using a simple three-step sequence (Figure 5). The six 2-O-
benzoyl esters were removed and replaced with acetyl esters to
give hexa-O-acetyl product 34 in 57% yield. The benzylic
protecting groups were removed en masse within 24 h by
hydrogenolysis (2 atm H2) catalyzed by 10% Pd on carbon in a
solution of THF:H2O (2:1 v/v) with 1 equiv of HCl added to
suppress O- to N-acetyl migration to give the desired SHCPS 1
in 65% after puriﬁcation by size exclusion chromatography and
lyophilization. No O- to N-acetyl migration was detected, nor
was any 2- to 3-O-acetyl migration detected on the non-
reducing end. Matrix-assisted laser desorption/ionization mass
spectrometry (MALDI-MS) of SHCPS 1 (Figure 6, panel A)
Figure 4. Initial coupling cycle to attach the ﬁrst disaccharide to the linker. Chemical evolutions in the ﬁrst of the coupling cycles whereby the
disaccharide donor 17 is attached to the linker synthon to initiate the saccharide backbone. Subsequent elaborations develop this compound to the
acceptor diol 23 ready for coupling to further disaccharides to extend the chain. Reagents and conditions: (a) TMSOTf 0.1 equiv, CH2Cl2, rt, 2 h;
(b) sodium methoxide, methanol, tetrahydrofuran, rt; (c) p-toluenesulfonic acid, acetone, 2,2-dimethoxypropane, rt, 2 h; (d) Dess-Martin Reagent,
CH2Cl2 (wet), rt, 24 h; (e) dichloromethane:methanol (1:1), 0 °C, NaBH4, 5 min; (f) benzoyl chloride, pyridine, CH2Cl2, 4-
(dimethylamino)pyridine, rt, 12 h; (g) acetic acid, H2O (4:1, v/v), 50 °C, 12 h. For complete reaction conditions see Supporting Information.
Bn = Benzyl; Bz = Benzoyl; Ac = acetyl; TCA = trichloroacetimidate; ADMB = 4-acetoxy-2,2-dimethyl butanoyl; Cbz = benzyloxycarbonyl.
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identiﬁed major peaks at m/z = 1427 and m/z = 1449
(calculated values: C60H99NO37 m/z = 1426.6; C60H99NO37Na
m/z = 1448.6). The 13C NMR and 1H NMR spectra of the
synthetic antigen 1 (Figure 6, panels B and C) were consistent
with this molecule being 1→3 linked 2-O-acetyl-6-deoxy-β-D-
manno-heptopyranose, which gave conﬁdence to proceed with
conjugation and immunogenicity studies.
Conjugation to Carrier Protein. Although SHCPS 1 was
likely to be of suﬃcient size to act as an epitope to generate
speciﬁc antibodies, it was considered to be unlikely to be
suﬃciently immunogenic on its own to stimulate antibodies
during immunization. Polysaccharides such as the manno-
heptopyranose CPS are generally T-independent type 2
antigens relying on cross-linking of surface immunoglobulin
molecules present on antigen-speciﬁc B cells to stimulate
antibody responses.46−48 With a molecular weight of 1524 Da,
SHCPS 1 is not large enough to act in this manner, and further
its small size makes rapid clearance from the body before
engaging with the immune system a real possibility. For larger
polysaccharides, conjugation to carrier proteins is the tradi-
tional method to allow polysaccharides to act as T-dependent
antigens with the concomitant boost in antibody responses,
promotion of class switching and increased B-cell memory
formation.49 Additional beneﬁts of this strategy for oligosac-
charides such as synthetic hexasaccharide 1 are that clustering
of multiple oligosaccharides on a single protein may act to
Figure 5. Iterative coupling cycles to assemble the target hexasaccharide 1. Chemical manipulations involved in the second and third coupling cycles
installing the disaccharide donor 17 onto the disaccharide diol acceptor 23 and subsequently the tetrasaccharide diol acceptor 30 to generate the full-
length hexasaccharide. Succeeding elaborations replace the six 2-O-benzoyl esters with acetyl esters to give hexa-O-acetyl hexasaccharide ready for
ﬁnal deprotection to give the target antigen 1. Reagents and conditions: (a) TMSOTf 0.1 equiv, CH2Cl2, rt, 2 h; (b) magnesium methoxide,
methanol, tetrahydrofuran, rt; (c) p-toluenesulfonic acid, acetone, 2,2-dimethoxypropane, rt, 2 h; (d) Dess-Martin Reagent, CH2Cl2 (wet), rt, 24 h;
(e) dichloromethane:methanol (1:1), 0 °C, NaBH4, 5 min; (f) benzoyl chloride, pyridine, CH2Cl2, 4-(dimethylamino)pyridine, rt, 12 h; (g) acetic
acid, H2O (4:1, v/v), 50 °C, 12 h; (h) trimethylorthobenzoate, CH2Cl2, CH3CN, cat. camphorsulfonic acid, rt, 1 h, then H2O, 5 h; (i) ytterbium(III)
triﬂuoromethanesulfonate, p-methoxybenzyl trichloroacetimidate, toluene, rt, 3 h; (j) NaOMe, methanol, tetrahydrofuran, rt, 12 h; (k) acetic
anhydride, pyridine, CH2Cl2, 4-(dimethylamino)pyridine, rt, 12 h, 57% over two steps; (l) 10% Pd/C, methanol, H2O, HCl (1 equiv), H2 (2 atm.),
rt, 43 h, 67%. For complete reaction conditions, see Supporting Information. Bn = Benzyl; Bz = Benzoyl; Ac = acetyl; ADMB = 4-acetoxy-2,2-
dimethyl butanoyl; Cbz = benzyloxycarbonyl.
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simulate a larger polysaccharide, and that the resulting
glycoconjugate may be retained for longer in the body giving
more time to engage with and stimulate the immune system. As
such, SHCPS was designed to incorporate an amine-terminated
alkyl linker to allow conjugation to a carrier protein. The
recombinant carrier protein was the nontoxic Hc domain of
tetanus toxin (TetHc), primarily chosen due to the presence of
known T-cell epitopes and because tetanus toxoid is used as the
carrier in a number of licensed glycoconjugate vaccines.50
Conjugation was eﬀected by linking hexasaccharide 1 to TetHc
using a glutaric acid linker as described by Bromuro et al.51 The
glycoconjugate was puriﬁed by size exclusion centrifugation and
lyophilized. The resulting glycoconjugate (TetHc-SHCPS) was
present as a slightly diﬀuse band with reduced mobility by SDS-
PAGE compared to unconjugated TetHc, indicating the
incorporation of glycan. The MALDI-MS data for the conjugate
clearly show successive signals at Δ = 1524 amu, attributable to
increasing valency of the fully intact hexasaccharide plus the
Figure 6. Analysis of SHCPS target antigen 1 and TetHc-SHCPS glycoconjugate. (A) MALDI-MS of SHCPS target antigen 1. (B)
1H NMR spectrum
of SHCPS target antigen 1.
1H NMR spectra were acquired in D2O with the HOD signal at 4.75 ppm serving as the internal reference. (C)
13C NMR
spectrum of SHCPS target antigen 1 with 1,4-dioxane (67.19 ppm) served as the internal standard. (D) MALDI-MS revealing 12 discrete peaks
reﬂecting the incorporation of between 1 and 12 SHCPS hexasaccharides per TetHc protein as indicated above each peak. Unconjugated TetHc
would be present as a peak at approximately m/z 53 000 as indicated. The increments match the expected mass of the hexasaccharide and linker
following incorporation using the selected chemistry (1524 Da per hexasaccharide incorporated). (E) SDS-PAGE with subsequent Coomassie
staining demonstrates the increased molecular weight of the TetHc-SHCPS glycoconjugate compared to unconjugated TetHc protein. No
unconjugated TetHc was visible in the glycoconjugate. Loading was with 3.2 μg of TetHc per lane and 3.4 μg and 6.8 μg of conjugate in the left and
right lanes respectively.
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glutarate linker. While 2-O to 3-O-Ac migration at the
nonreducing terminal residue cannot be unequivocally ruled
out, all of the Ac esters in the hexasaccharide antigen are
present (Figure 6, panels D and E). It was possible to see 12
discrete peaks arranged in a generally normal distribution with a
mean of approximately 6.5 hexamers per TetHc protein (15%
glycan by weight), which was consistent with the degree of
reduced mobility by SDS-PAGE. No unconjugated TetHc was
visible by mass spectrometry or by SDS-PAGE.
Conjugate Immunogenicity. To assess whether the
synthetic hexasaccharide was capable of raising relevant
immune responses, groups of ﬁve BALB/c mice were
immunized using a prime-boost-boost strategy with the
TetHc-SHCPS glycoconjugate or a mix of unconjugated
SHCPS and TetHc. Following the ﬁnal boost, sera was recovered
from tail veins and titers of IgG and IgM recognizing puriﬁed
native CPS were determined by ELISA (Table 1). Mice
receiving the mix of SHCPS and TetHc had a CPS-speciﬁc
antibody titer which was below the limit of detection in this
assay. In contrast, all of the mice receiving the TetHc-SHCPS
glycoconjugate had detectable levels of IgG and IgM
recognizing native CPS, demonstrating that the synthetic
approach utilized here successfully generated immunologically
relevant glycoconjugates and also the necessity for conjugation
to a carrier protein for the development of detectable immune
responses. There was a bias toward IgG in the responses of four
of the ﬁve mice immunized with TetHc-SHCPS, as is consistent
with responses observed for other glycoconjugate vaccines
where there is expected to be a switch from IgM to IgG
production. Interestingly, the titer of the CPS-speciﬁc IgG
response to this glycoconjugate (reciprocal end point titer of
25−400) is several orders of magnitude lower than what has
previously been observed for responses generated against native
CPS conjugates (reciprocal end point titer of ∼100 00017,18).
The reason for this disparity is unclear at present, although one
hypothesis currently being evaluated involves the relative
abundance within the native and synthetic CPS molecules of
the repeating internal epitope (present in great excess in native
CPS) and the terminal epitope at the nonreducing end of the
glycan (present in relatively greater abundance in synthetic
CPS).. It is possible that antibodies raised to diﬀerent parts of
the CPS molecule play diﬀerent roles in protection of the host,
for example, opsonizing antibodies may only be generated in
response to certain epitopes.
Protective Eﬃcacy. Murine models of melioidosis using
BALB/c mice and the intraperitoneal route of infection are well
established and have been used extensively to evaluate vaccine
candidates (for reviews, see refs 8−10,52,53). The protective
eﬃcacy of the TetHc-SHCPS glycoconjugate was assessed in two
independent challenge studies (see Experimental Procedures
section for details of the schedules), starting with a preliminary
study to establish approximate p values and eﬀect size to inform
power calculations for conﬁrmatory studies (groups received;
(i) TetHc-SHCPS glycoconjugate and (ii) adjuvant only;
challenge was 1.02 × 105 colony forming units (CFU) of B.
pseudomallei K96243 (approximately 137 × LD50); n = 6 per
group). The results from the preliminary study were such that a
similarly sized study was suﬃcient to verify the ﬁndings.
Additional groups were included in this study to further
examine the protection observed (groups received; (i)
TetHc-SHCPS glycoconjugate; (ii) adjuvant only; (iii) a mix
of unconjugated SHCPS and TetHc protein; and (iv) SHCPS
only; challenge was with 8.9 × 104 CFU of B. pseudomallei
K996243 (approximately 120 × LD50); n = 6 per group). The
survival curves of the groups receiving adjuvant only or the
TetHc-SHCPS glycoconjugate were examined to assess con-
sistency between the two studies and were not signiﬁcantly
diﬀerent (p = 0.1380 and p = 0.3112, respectively). Therefore,
further analysis was conducted using pooled data sets (Figure
7).
As expected and in line with the high challenge doses used in
these studies (≥120 × LD50), all control mice immunized with
adjuvant succumbed rapidly to disease, with 11 of 12 mice
succumbing within 3 days. In contrast, only 4 of the 12 mice
immunized with TetHc-SHCPS had succumbed to disease by
the end of the study at day 35. Of the surviving eight mice, no
bacteria were detectable in the lungs, liver, and spleen of three,
suggesting, at least within the conﬁnes of the organs tested and
the limit of detection of the assay, that these mice had cleared
infection. The remaining ﬁve mice had bacteria detectable in
the liver and spleen (2 of 5 mice) or in lungs, liver, and spleen
(3 of 5 mice). The highest numbers of bacteria were present in
the spleen (median 2.7 × 106 CFU, range 2.0 × 104 CFU to 3.2
× 107 CFU) with lower levels in the lungs (median 2.3 × 102
CFU, range 8.0 × 100 CFU to 2.5 × 103 CFU) and liver
(median 3.3 × 103 CFU, range 4.0 × 101 CFU to 6.6 × 104
CFU) suggesting an ongoing infection with the mice likely to
succumb to infection without further medical intervention.
Such a high level of survival, and indeed the presence of
apparent bacterial clearance in a subset of mice, was unexpected
given the very low level of antigen-speciﬁc antibodies detectable
after immunization. Previous studies have undoubtedly
indicated the need for humoral immunity in vaccine-induced
protection (for reviews, see refs 8−10), and although there
have only been limited studies where antibody titers have been
directly linked to outcome on an individual animal basis,54 it is
clear from other studies using conjugated and unconjugated
native capsular polysaccharide that groups with higher antigen-
speciﬁc antibody titers fare better than groups with lower titers.
Previous work has identiﬁed diﬀerences between the
immunogenicity of terminal and internal polysaccharide
epitopes in model antigens55 and some evidence exists with
Francisella tularensis that the avidity of antibodies targeting
terminal epitopes can be higher than for antibodies targeting
internal epitopes.56 It may be that, although stimulating a
Table 1. Antibody Titers versus Native CPS Following
Immunization with TetHc-SHCPS Glycoconjugate
antibody reciprocal
end point titera
vaccine received IgM IgG IgG:IgM ratio
TetHc - SHCPS conjugate
b 25 200 8
50 100 2
50 25 0.5
200 400 2
25 25 1
TetHc/SHCPS mix
b <25 <25 N/A
<25 <25 N/A
<25 <25 N/A
<25 <25 N/A
<25 <25 N/A
aThe limit of detection for this assay was a reciprocal end point of 25.
bEach row represents the result from an individual mouse.
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relatively low titer of antibody, the small size and diﬀerent
spectrum of epitopes within SHCPS promotes development of
highly functional antibodies responsible for the high levels of
protection observed. This possibility, and methods to exploit it
for improved vaccines, is currently under study.
In summary, this is the ﬁrst demonstration of the chemical
synthesis of an immunologically relevant and protective
hexasaccharide fragment of the capsular polysaccharide of B.
pseudomallei and serves as the rational starting point for the
development of an eﬀective licensed vaccine for this emerging
infectious disease. The synthetic B. pseudomallei CPS hexamer
material lacks impurities such as endotoxin, and is generated
with limited batch-to-batch variation and high quality control
standards which are intrinsic to process manufacturing. In
addition, the ability to install a functional amine for directed
conjugation, and the lack of requirement for containment
facilities renders this approach to accessing CPS antigen as a
suitable starting point for industrial process development
toward licensure. Further, the modular disaccharide strategy
described herein is broadly applicable for synthesizing other
glycans containing C-6 homologated monosaccharide units in
general, and for those connected by 1,2-β-manno-conﬁgured
glycosides in particular.
■ EXPERIMENTAL PROCEDURES
Chemical Synthesis. Detailed synthetic procedures and
characterization data are available online; see Supporting
Information.
Glycoconjugate Generation and Analysis. Recombinant
tetanus toxin Hc fragment (TetHc; incorporating amino acids
865−1315 from TetX (NP_783831) of Clostridium tetani E88)
was puriﬁed from E. coli BL21 (pKS1-TetHc) using the method
of Sinha et al.57 with modiﬁcations as previously described.58
The TetHc-SHCPS glycoconjugate was manufactured by linking
SHCPS to TetHc protein using the method of Bromuro et al.
51
Brieﬂy, hexasaccharide antigen (1) (3.0 mg, 4.3 μmol) was
dissolved in H2O (100 μL) and DMSO (900 μL) was added
followed by triethylamine (5 μL). Solid disuccinyl glutarate
(DSG) was added and the suspension was vortexed until a clear
solution resulted (10 s). The solution was incubated at room
temperature for 2 h then the reaction solution was applied
directly to the top of a Sephadex G-10 column (2.5 cm
diameter × 14 cm height) that had been pre-equilibrated with
pH 4 water. The column was eluted by gravity with pH 4 water.
4 mL fractions were collected and analyzed by TLC for
carbohydrate content (anisaldehyde staining). Carbohydrate-
containing fractions were combined and concentrated to
dryness, then reconstituted in 10 mM phosphate-buﬀered
saline (PBS, pH 7.0, 1000 μL). This solution was added to a
solution of TetHc protein (3.08 mg) in 10 mM PBS (1000 μL)
and the reaction solution was incubated for 9.5 h at 4 °C. The
conjugate was puriﬁed by repeated centrifugation through a 10
kDa MWCO Amicon ﬁlter until no carbohydrate (free antigen)
could be detected in the ﬁltrate (6 × 3 mL, 10 mM PBS, pH
7.0). The concentrate containing the conjugate was lyophilized
and reconstituted in water then sampled for analysis by SDS-
PAGE and MALDI-MS. Absolute protein content was
determined using a modiﬁed Bradford assay (Bio-Rad) using
unconjugated TetHc as a reference standard.
Ethics Statement. Investigations involving animals were
carried out according to the requirements of the UK Animal
(Scientiﬁc Procedures) Act 1986 under project licenses PPL
30/2623 and PPL 30/3026. These project licenses were
approved following an ethical review by Dstl’s Animal Welfare
and Ethical Review Body.
Animal Immunization and Infection. Please see
Supporting Information for detailed information on animal
care and housing. Studies were performed using female BALB/
cAnNCrl mice (BALB/c; Charles River UK). Mice were
immunized via the intraperitoneal route on days 0, 14, and 28
with the various antigens. The mice received 66 μg of
TetHc-SHCPS glycoconjugate per dose (containing 10 μg of
SHCPS and 56 μg of TetHc) or matching amounts of
unconjugated antigen as appropriate. All antigens were
formulated in adjuvant containing monophosphoryl lipid A
from Salmonella minnesota (25 μg per mouse per dose) and
synthetic trehalose dicorynomycolate (25 μg per mouse per
dose) as an oil-in-water emulsion of 2% squalene and 0.2%
Tween 80 (Sigma Adjuvant System, Sigma-Aldrich). Antigen
and adjuvant were combined and vortexed thoroughly to mix
immediately before administration to mice. Challenges with B.
pseudomallei K96243 were delivered at day 63 via the
intraperitoneal route. The B. pseudomallei K96243 used in
this study was a low passage descendant of the original stock
from which genomic DNA was prepared and sequenced by
Holden et al.59 Prior to use in this study, this stock of strain
Figure 7. Protective eﬃcacy of TetHc-SHCPS glycoconjugate. (A)
Kaplan−Meier plot displaying survival of immunized BALB/c mice
over 35 days following intraperitoneal infection with 120 to 137 ×
LD50 of B. pseudomallei strain K96243. (B) Data table detailing
signiﬁcance after analyzing the survival data using a Log-Rank (Mantel-
Cox) test. The TetHc-SHCPS glycoconjugate oﬀers signiﬁcantly better
protection than all the other vaccines tested. Median survival time and
clearance in surviving mice is indicated.
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K96243 was veriﬁed as being sequence type 10 using the
multilocus sequence typing scheme of Godoy et al.60 To
prepare challenge material, B. pseudomallei K96243 was
inoculated from a glycerol stock into 100 mL L-broth and
incubated for 24 h at 37 °C with shaking (180 rpm). The
OD590 was adjusted to 0.4 (corresponding to approximately 4 ×
108 CFU/mL) and diluted in L-broth to the desired
concentration for challenge. For organ bacterial enumeration
at the end of study, animals were culled and organs removed.
These were mashed through 40 μm sieves into PBS, serially
diluted, and plated onto L-agar.
Analysis of Antibody Responses. Approximately 0.1 mL
of blood was collected from the tail veins of mice 14 days after
the ﬁnal immunizations were performed and serum was
removed and stored at −20 °C until required. Responses
directed against native CPS antigen were assessed by ELISA
essentially as previously described17 using native CPS puriﬁed
from B. thailandensis E555::wbiI (pKnock-Km)61 to coat the
ELISA plates. A reading of twice background or above was
considered positive and the titer was determined to be the
reciprocal of the ﬁnal positive dilution.
Data Analysis. All graphs were produced and analysis
conducted using the program GraphPad PRISM v 6.0. Survival
data was analyzed using a log rank (Mantel-Cox) test.
Signiﬁcance was assessed at the 95% conﬁdence level.
ChemBioDraw Ultra v 13.0 was used for drawing compounds
and reaction schemes. GNU Image Manipulation Program
(GIMP) v 2.8 was used to assemble ﬁgures into their ﬁnal
format.
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S. M., Dennison, S. M., Jaeger, F. H., Anasti, K., Stewart, S., Blinn, J.
H., et al. (2013) Chemical Synthesis of Highly Congested gp120 V1V2
N-Glycopeptide Antigens for Potential HIV-1-Directed Vaccines. J.
Am. Chem. Soc. 135, 13113−13120.
(22) Heuckendorff, M., Bols, P. S., Barry, C. B., Frihed, T. G.,
Pedersen, C. M., and Bols, M. (2015) β-Mannosylation with 4, 6-
benzylidene protected mannosyl donors without preactivation. Chem.
Commun. 51, 13283−13285.
(23) Marchetti, R., Dillon, M. J., Burtnick, M. N., Hubbard, M. A.,
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Taŕraga, A. M., Atkins, T., Crossman, L. C., Pitt, T., Churcher, C.,
Mungall, K., Bentley, S. D., et al. (2004) Genomic plasticity of the
causative agent of melioidosis. Proc. Natl. Acad. Sci. U. S. A. 101,
14240−14245.
(60) Godoy, D., Randle, G., Simpson, A. J., Aanensen, D. M., Pitt, T.
L., Kinoshita, R., and Spratt, B. G. (2003) Multilocus Sequence Typing
and Evolutionary Relationships among the Causative Agents of
Melioidosis and Glanders, Burkholderia pseudomallei and Burkholderia
mallei. Journal of Clinical Microbiology 41, 2068−2079.
(61) Champion, O. L., Gourlay, L. J., Scott, A. E., Lassaux, P.,
Conejero, L., Perletti, L., Hemsley, C., Prior, J., Bancroft, G., and
Bolognesi, M. (2016) Immunisation with proteins expressed during
chronic murine melioidosis provides enhanced protection against
disease. Vaccine 34, 1665.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.5b00525
Bioconjugate Chem. 2016, 27, 1435−1446
1446
